Sin nombre virus full-length m segment-based dna vaccines
AssigneeThe United States of America, as rep. by the Sec'y of the Army, for U.S. Army Medical Research Insti
InventorJAY HOOPER
Life of this patent
Estimating the term…
Abstract
The invention contemplates a new synthetic, codon-optimized Sin Nombre virus (SNV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The SNV ORF was cloned into a plasmid to form the first stable recombinant SNV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a vaccine system, and is useful to protect mammals against infection with Sin Nombre virus.
Claims21
1-3. (canceled)
The peptide encoded by the nucleic acid sequence of claim 1, which is set forth in SEQ ID NO:4.
5-9. (canceled)
A vaccine composition comprising an effective immunizing amount of SNV plasmid DNA, which plasmid DNA comprises the recombinant DNA construct of claim 5, and a pharmacologically acceptable carrier, and optionally an adjuvant.
A Sin Nombre Virus vaccine comprising a composition comprising inert particles and a nucleic acid coated onto the inert particles producing nucleic acid coated particles, said nucleic acid comprising a promoter operative in the cells of a mammal and a recombinant Sin Nombre Virus nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3.
A method for inducing a protective immune response against Sin Nombre virus infection in a mammal, comprising the step of administering a composition comprising an effective immunizing amount of SNV plasmid DNA, which plasmid DNA comprises the recombinant DNA construct of claim 5;
- and a pharmacologically acceptable carrier.
A therapeutic composition for ameliorating symptoms after onset of Sin Nombre virus infection comprising antibodies specific for peptides encoded by the nucleic acid of claim 3.
A post-exposure prophylactic against Sin Nombre virus infection in someone who has been exposed to Sin Nombre virus comprising a composition comprising polyclonal antibodies obtained from a population of human or animal vaccines vaccinated with a Sin Nombre virus DNA vaccine comprised of a plasmid expressing SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3.
A method for producing pseudotyped virions or SNV glycoprotein-containing cells, comprising the step of culturing the recombinant DNA construct of claim 5, under conditions that pseudotyped virions or SNV glycoprotein is produced.
Dependencies are inferred from the claim text.